Business Wire

WorldFirst’s 1688 Global Sourcing Integration Sees Adoption Surge as SME Buyers Seek Competitive Edges

8.9.2023 06:27:00 EEST | Business Wire | Press release

Share

WorldFirst, a one-stop global payment and financial services platform for SMEs engaged in cross-border trade, reported that international SME buyers have increasingly adopted the WorldFirst Cross-border Pay solution for 1688, one of China's top wholesale marketplaces, as SMEs worldwide seek cost-effective sourcing options to stay competitive.

During the first eight months of 2023, turnover generated by WorldFirst SME customers which sourced from 1688’s vast product marketplace through Cross-border Pay increased by over 50% to more than 22 billion yuan, or 3.03 billion US dollars. The number of new SMEs who signed up for the solution rose nearly 20%. Stationaries, petting products, gardening supplies, toys, and storage containers were among the most popular goods for these international buyers.

“We understand the immense potential that lies in helping SMEs to compete on a global scale," said Daniel Chua, Head of Commercial for Southeast Asia, WorldFirst. "By integrating with 1688, we aim to help businesses of all sizes to efficiently source products from one of the world's largest wholesale markets, regardless of their location. This integration underscores our commitment to helping SMEs thrive globally."

With the explosive growth of e-commerce, SMEs have increasingly turned to platforms like 1688 for diverse sourcing options. However, navigating the complexities of international payments and currency exchanges has historically posed challenges for these businesses. As an official payment partner with 1688, WorldFirst collaborated with the marketplace to jointly launch Cross-border Pay in 2019, aiming to address these pain points and streamline the way SMEs access and transact with suppliers on 1688.

WorldFirst Cross-border Pay offers international buyers an option to make payments to 1688 sellers without the need to set up an onshore bank account in China. The buyers will also benefit from highly competitive foreign exchange rates, as inbound payment is settled at the offshore yuan rate.

Cross-border Pay usage also increased in Southeast Asian markets where the solution is available. During the first eight months, Cross-border Pay turnover, or transaction volume, by buyers from Singapore, Malaysia and Thailand grew 21%, 11%, and 11%, respectively, from the same period a year earlier. The number of new Cross-border Pay customers from Singapore more than doubled and that from Malaysia surged 69% on year.

Since its launch in 2019, Cross-border Pay has experienced consistent year-on-year growth in annual turnover. “This shows a global payment solution designed to continuously assists SMEs in saving costs and time in international trade is a crucial need of businesses today. And we plan to roll out Cross-border Pay to more markets to help SMEs stay competitive, expand their product offerings, and ultimately drive growth,” said Chua.

Cross-border Pay is currently available primarily in Southeast Asia, Australia, and other Asia Pacific markets. WorldFirst, a member of Ant Group, plans to introduce the solution to the United Kingdom and continental European markets in the coming months.

With 19 years’ experience in facilitating cross-border payments, WorldFirst has consistently strived to offer ground-breaking solutions that help SMEs grow globally. At the 2023 INCLUSION·Conference on the Bund, held from Thursday to Saturday in Shanghai, China, WorldFirst unveiled a set of upgraded features. Notably, the latest enhancements will allow China-based sellers to effortlessly set up a store on over 30 overseas marketplaces through a single application.

Launched in 1999, 1688 is China’s largest integrated domestic wholesale marketplace in 2021 by net revenue, according to Analysys. It provides sourcing and online transaction services by connecting manufacturers and wholesale sellers to wholesale buyers in China. In recent years, 1688, a business of Alibaba Group, has attracted a growing number of cross-border buyers to access its vast array of products. According to 1688, there are 5.7 million cross-border buyers, contributing to a quarter of its annual GMV.

About WorldFirst

WorldFirst was founded in 2004 and joined Ant Group in 2019. Through the World Account, WorldFirst is meeting the needs of SMEs engaged in international trade or business, both online via marketplaces or websites, as well as offline to support importers and exporters. This includes global collection (receiving payments), making payments, currency conversion, risk management, and supply chain financing to help WorldFirst customers reduce costs, improve turnover efficiency to generate more revenue and sales, and quickly capture global business opportunities. WorldFirst serves one million customers worldwide and is connected to over 100 marketplaces. To learn more about WorldFirst at https://www.worldfirst.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Martin Mou
mou.xu@worldfirst.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye